Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 869-877

  Swiercz, Rafal ^a   Wolfe, Jeremy D ^a   Zaher, Aiman ^a   Jankun, Jerzy ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUCASIAN; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; KIDNEY CANCER; KIDNEY CARCINOMA; MALE; NEGRO; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PHENOTYPE; PLASMINOGEN; PLASMINOGEN INACTIVATORS; RECEPTORS, CELL SURFACE; SEX FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031942989     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wilson, M. J., and Sinha, A. A. Plasminogen activator and metallo-protease activities of DU-145, PC-3 and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with invasive behavior. Cell. Mol. Biol. Res., 39: 751-760, 1993.
2. Jankun, J., Merrick, H. W., and Goldblatt P. J. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. Cell. Biochem., 53: 135-144, 1993.
3. Bianchi, E., Cohen, R. L., Thor, A. T., Todd, R. F., III, Mizukami, I. F., Lawrence, D. A., Ljung, B. M., Shuman, M. A., and Smith, H. S. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res., 54: 861-866, 1994.
4. Ganesh, S., Sier, C. F., Griffioen, G., Vloedgraven, H. J., deBoer, A., Welvaart, K., van de Velde, C. J., van Krieken, J. H., Verheijen, J. H., Lamers, C. B., and Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54: 4065-4071, 1994.
5. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Dano, K., and Brunner, N. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
6. Kinder, D. H., Berger, M. S., Mueller, B. A., and Silber, J. R. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain. Oncol. Res., 5: 409-414, 1993.
7. Hienert, G., Kirchheimer, J. C., Pfluger, H., and Binder, B. R. Urokinase-type plasminogen activator as a marker for the formation of distant metastasis in prostatic carcinomas. J. Urol., 140: 1466-1469, 1988.
8. Hofmann, R., Lehmer, A., Buresch, M., Hartung, R., and Ulm, K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer (Phila.), 78: 487-492, 1996.
9. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139-266, 1985.
10. Markus, G. The relevance of plasminogen activators to neoplastic growth. A review of recent literature. Enzyme (Basel), 40: 158-172, 1988.
11. Schmitt, M., Janicke, F., Moniva, N., Chucholowski, N., Pache, L., and Graeff, H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe-Seyler, 373: 611-622, 1992.
12. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays, 15: 105-111, 1993.
13. Estreicher, A., Wohlwend, A., Belin, D., Schleuning, W. D., and Vassalli, J. D. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J. Biol. Chem., 264: 1180-1189, 1989.
14. Shirasuna, K., Saka, M., Hayashido, Y., Yishioka, H., Sugiura, T., and Matsuya, T. Extracellular matrix production and degradation by adenoic cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res., 53: 147-152, 1993.
15. Tryggvason, K., Hoyhtya, M., and Salo, T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta, 907: 191-217, 1987.
16. Ohnishi, S. T., and Barr, J. K. A simplified method of quantitating protein using the biuret and phenol reagents. Anal. Biochem., 86: 193-200, 1978.
17. Wordinger, R. J., Miller, G. W., and Nicodemus, D. S. Manual of Immunoperoxidase Techniques. Chicago: American Society of Clinical Pathologist Press, 1987.
18. Chucholowski, N., Schmitt, M., Rottenberg, P., Schuren, E., Moniva, N., Groetzki, L., Wilhelm, O., Weilde, U., Fanicke, F., and Graeff, H. Flow cytofluorometric analysis of the urokinase receptor (uPAR) on tumor cells by fluorescent uPA-ligand or monoclonal antibody 3936. Fibrinolysis, 6 (Suppl. 4): 95-102, 1992.
19. Hazard-Murno, B. Statistical Methods in Health Care Research. Philadelphia: Lippincott-Raven Publishers, 1997.
20. Gaylis, F. D., Keer, H. N., Wilson, M. J., Kwaan, H. C., Sinha, A. A., and Kozlowski, J. M. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J. Urol., 142: 193-198, 1989.
21. Keer, H. N., Gaylis, F. D., Kozlowski, J. M., Kwaan, H. C., Bauer, K. D., Sinha, A. A., and Wilson, M. J. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate, 18: 201-214, 1991.
22. Nishino, N., Aoki, K., Tokura, Y., Sakaguchi, S., Takada, Y., and Takada, A. The urokinase type of plasminogen activator in cancer of digestive tracts. Tromb. Res., 50: 527-535, 1988.
23. Larsson, G., Larsson, A., and Astedt, B. Tissue plasminogen activator and urokinase in normal, diaplastic, and cancerous squamous epithelium and uterine cervix. Thromb. Haemostasis, 58: 822-826, 1987.
24. Saito, K., Nagashima, M., and Iwata, M. The concentration of tissue plasminogen activator and urokinase in plasma of patients with ovarian and uterine tumors. Thromb. Res., 58: 355-366, 1990.
25. Duffy, M. J., Reilley, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., and Andreasen, P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
26. Jänicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, K., and Graeff, H. The urokinase plasminogen activator (uPA) is a potent predictor of early relapse in breast cancer. Fibrinolysis, 4: 69-98, 1990.
27. Schmitt, M., Jänicke, F., Pache, L., Harbeck, N., and Graeff, H. Urokinase (uPA) is a strong independent prognostic factor in node-negative breast cancer. Fibrinolysis, 6 (Suppl. 2): 57, 1992.
28. Hofmann, R., Lehmer, A., Hartung, R., Robrecht, C., Buresch, M., and Grothe, F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J. Urol., 155: 858-862, 1996.
29. Frist, S. T., Taylor, H. A., Jr., Kirk, K. A., Grammer, J. R., Li, X. N., Grenett, H. E., and Booyse, F. M. Expression of PAI-1, t-PA and u-PA in cultured human umbilical vein endothelial cells derived from racial groups. Thromb. Res., 77: 279-290, 1995.
30. Iso, H., Folsom, A. R., Koike, K. A., Sato, S., Wu, K. K., Shimamoto, T., Iida, M., and Komachi, Y. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: correlates in nonsmoking Japanese and Caucasian men and women. Thromb. Haemostasis, 70: 475-480, 1993.
31. Dayal, H., and Kinman, J. Epidemiology of kidney cancer. Semin. Oncol., 10: 366-377, 1983.
32. Lynch, C. F., and Cohen, M. B. Urinary system. Cancer (Phila.), 75: 316-329, 1995.
33. Friori, E., Leone, G., Gazzanelli, S., Ansali, A., Lutzu, S. E., Boccuzzi, M., and Baccarini, A. Renal cell carcinoma in adolescents. A case report and review of literature. Panminerva Med., 38: 121-128, 1996.
34. Pappot, H., Gradsvoll, H., Romer, J., Pedersen, A. N., Glondahl-Hansen, J., Pyke, C., and Brunner, N. Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe-Seyler, 376: 259-267, 1995.